GenScript Launches Antibody Sequencing Service Geared Toward Innovation

Piscataway, NJ (PressExposure) September 04, 2009 -- Internationally recognized biology contract research organization, GenScript US Inc. has launched antibody sequencing services which aim to speed up antibody drug discovery and patent applications.

Antibody sequencing is a crucial component of antibody engineering. It may lead to new intellectual progress. Knowing the sequence of your monoclonal antibody is a fundamental step toward optimizing its functions. "GenScript has the ability to sequence most monoclonal antibodies and our service is geared to facilitate the development of a lead therapeutic candidate with enhanced properties, granting them with better potency, productivity, and antigenicity. It also helps creating research antibodies configured with a more optimal constant regions." says Frank Zhang, PHD, president of GenScript.

GenScript can raise cell lines according to flexible sequencing specifications. The antibody sequencing service is ISO 9001:2000 certified and can be applied to patent applications, database banking, and antibody therapeutics.

GenScript is a contract research organization (CRO) specialized in biological research and drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bio-reagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has become a world-leading Biology CRO and the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China.

About GenScript USA Inc.

For further information, please contact:
Sally Wang
Executive Vice President
GenScript USA INC.
1-(732) 885-9188

Press Release Source:

Press Release Submitted On: September 03, 2009 at 9:03 pm
This article has been viewed 40736 time(s).